51 min ago | Medgadget
Focala One Robotic High-Intensity Focused Ultrasound for Prostate Cancer Gets Green Light in EU
EDAP TMS of Vaulx-en-Velin, France received CE Mark approval for its Focal - One robotic High-Intensity Focused Ultrasound system for non-invasive treatment of prostate cancer.
4 hrs ago | SeacoastOnline
Active surveillance helps prostate cancer treatment
The Maine Coalition to Fight Prostate Cancer has been a strong advocate for prostate cancer screening for most men.
5 hrs ago | PhysOrg Weblog
Preventing eggs' death from chemotherapy
Young women who have cancer treatment often lose their fertility because chemotherapy and radiation can damage or kill their immature ovarian eggs, called oocytes.
9 hrs ago | CiteULike
Searching standard parameters for volumetric modulated arc therapy (VMAT) of prostate cancer
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
13 hrs ago | Science Daily
Exposure to BPA in developing prostate increases risk of later...
"This is the first direct evidence that exposure to BPA during development, at the levels we see in our day-to-day environment, increases the risk for prostate cancer in human prostate tissue," said Prins, professor of physiology and director of the andrology laboratory in urology at the UIC College of Medicine.
Dr. Roach: To manage opposing conditions, doctors balance risks and benefits of medications
Dear Dr. Roach : In 2008, I was treated for prostate cancer with radiation. A couple of months later, I started passing blood during bowel movements.
A simple test that could save your life
Illnesses are a rather private thing, but I am persuaded that in this case what happened to me, and the good fortune that I was blessed with in terms of having a level headed and perceptive chum or two and an excellent GP, might well apply to a number of you.
The silent killer of men, and why they won't find out
Prostate cancer occurs in African-American men 60 percent more often than Caucasian men, and when they are diagnosed, it's more likely to be in advance stages.
Wait-and-see may be best for early prostate cancer
Watching and routinely examining men with early, slow-growing prostate cancer is more effective and cheaper than sending them to surgery or radiation right away, according to a new study.
New Medication Treats Drug-Resistant Prostate Cancer in the Laboratory
Newswise - A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model.
New medication treats drug-resistant prostate cancer in the laboratory
A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model.
New drug proving effective in attacking advanced prostate cancer
Franciscan St. Francis Health Cancer Center today is the first medical facility in Indiana to use a new drug to treat men with advanced prostate cancer.
Riders participating in the annual Rally for Dad depart the Northeast Cancer Centre and make their way up Paris Street.
Do It For Dad raises record amount for Vernon prostate cancer care
By Staff Writer - Vernon Morning Star Published: June 17, 2013 11:00 AM Updated: June 17, 2013 11:45 AM The event at Coldstream Ranch raised a record $38,500 Sunday.
J&J to buy prostate cancer firm Aragon Pharma
Under the agreement, expected to close during the third quarter, J&J will pay $650 million upfront and potential milestone payments of up to $350 million for Aragon, which focuses on hormonally-driven cancers.
Johnson & Johnson Acquires Prostate Cancer Drug
This morning, Johnson & Johnson announced it would buy Aragon Pharmaceuticals for as much as $1 billion.
J&J to Buy Aragon Pharmaceuticals for Prostate Cancer Drug
Johnson & Johnson, the world's biggest maker of health-care products, agreed to pay as much as $1 billion to buy Aragon Pharmaceuticals Inc. and gain the closely held company's experimental prostate cancer drug.
Mount Sinai researchers present several new studies at ENDO 2013
Mount Sinai researchers present new data at ENDO 2013, The Endocrine Society's Annual Meeting & Expo June 15-18 in San Francisco Researchers from the Icahn School of Medicine at Mount Sinai will present several new studies at ENDO 2013, The Endocrine Society's Annual Meeting & Expo from June 15-18 in San Francisco.
The modified Glasgow prognostic score in prostate cancer: results...
As the incidence of prostate cancer continues to rise steeply, there is an increasing need to identify more accurate prognostic markers for the disease.
Raising awareness with the PROST-8k run/walk
Dr. Bryan Mehlhaff of the institute was one of the 300 people that turned out for the PROST-8k run/walk.